CN106932347A - 一种美洛西林酸及其质量指标检测方法 - Google Patents
一种美洛西林酸及其质量指标检测方法 Download PDFInfo
- Publication number
- CN106932347A CN106932347A CN201710347177.2A CN201710347177A CN106932347A CN 106932347 A CN106932347 A CN 106932347A CN 201710347177 A CN201710347177 A CN 201710347177A CN 106932347 A CN106932347 A CN 106932347A
- Authority
- CN
- China
- Prior art keywords
- solution
- sample
- test
- mezlocillin
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960000198 mezlocillin Drugs 0.000 title claims abstract description 44
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 title claims abstract description 44
- 238000001514 detection method Methods 0.000 title claims abstract description 15
- 238000012360 testing method Methods 0.000 claims abstract description 81
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000002158 endotoxin Substances 0.000 claims abstract description 14
- 238000003556 assay Methods 0.000 claims abstract description 12
- 229920000642 polymer Polymers 0.000 claims abstract description 9
- 239000013557 residual solvent Substances 0.000 claims abstract description 9
- 239000000243 solution Substances 0.000 claims description 97
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 24
- 239000013558 reference substance Substances 0.000 claims description 22
- 239000013641 positive control Substances 0.000 claims description 18
- 238000007689 inspection Methods 0.000 claims description 16
- 238000005070 sampling Methods 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 15
- 239000008363 phosphate buffer Substances 0.000 claims description 13
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 12
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 238000010812 external standard method Methods 0.000 claims description 10
- 239000012467 final product Substances 0.000 claims description 10
- 239000013642 negative control Substances 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 6
- 230000003287 optical effect Effects 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 230000035945 sensitivity Effects 0.000 claims description 5
- SQAUMYIUCBBCCY-UHFFFAOYSA-N C(CC)C1=CC=CC=C1.N#CC#N Chemical compound C(CC)C1=CC=CC=C1.N#CC#N SQAUMYIUCBBCCY-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 229920005654 Sephadex Polymers 0.000 claims description 3
- 239000012507 Sephadex™ Substances 0.000 claims description 3
- 241000534944 Thia Species 0.000 claims description 3
- 125000003368 amide group Chemical group 0.000 claims description 3
- 239000003708 ampul Substances 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- -1 dimethyl siloxane Chemical class 0.000 claims description 3
- 231100000284 endotoxic Toxicity 0.000 claims description 3
- 230000002346 endotoxic effect Effects 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 238000011067 equilibration Methods 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims 2
- 238000007789 sealing Methods 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical group CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims 1
- 239000000741 silica gel Substances 0.000 claims 1
- 229910002027 silica gel Inorganic materials 0.000 claims 1
- 238000010998 test method Methods 0.000 claims 1
- 238000004811 liquid chromatography Methods 0.000 abstract description 7
- 239000000523 sample Substances 0.000 description 44
- 230000033228 biological regulation Effects 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- KCVTVKMPZQSSNU-UHFFFAOYSA-N 2-pyridin-4-ylethanethioyl chloride Chemical compound ClC(=S)CC1=CC=NC=C1 KCVTVKMPZQSSNU-UHFFFAOYSA-N 0.000 description 2
- FUSNOPLQVRUIIM-UHFFFAOYSA-N 4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-n-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide Chemical compound O=C1NC(C)(C)CN1C(N=C1N)=NC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 FUSNOPLQVRUIIM-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- SEGLCEQVOFDUPX-UHFFFAOYSA-N di-(2-ethylhexyl)phosphoric acid Chemical compound CCCCC(CC)COP(O)(=O)OCC(CC)CCCC SEGLCEQVOFDUPX-UHFFFAOYSA-N 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002270 exclusion chromatography Methods 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- 229910000377 hydrazine sulfate Inorganic materials 0.000 description 2
- 239000012493 hydrazine sulfate Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- 229960004011 methenamine Drugs 0.000 description 2
- 229960001994 mezlocillin sodium Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical class [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 201000005060 thrombophlebitis Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical class N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 231100000734 genotoxic potential Toxicity 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/29—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using visual detection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D499/44—Compounds with an amino radical acylated by carboxylic acids, attached in position 6
- C07D499/48—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical
- C07D499/58—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical
- C07D499/64—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical by nitrogen atoms
- C07D499/68—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical by nitrogen atoms with aromatic rings as additional substituents on the carbon chain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/02—Investigating particle size or size distribution
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/21—Polarisation-affecting properties
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
Landscapes
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
Abstract
Description
级号 | 0.5 | 1 | 2 | 3 | 4 |
浊度标准原液/ml | 2.50 | 5.0 | 10. | 30 | 50 |
水/ml | 97.50 | 95.0 | 90.0 | 70.0 | 50.0 |
级号 | 0.5 | 1 | 2 | 3 | 4 |
浊度标准原液/ml | 2.50 | 5.0 | 10. | 30 | 50 |
水/ml | 97.50 | 95.0 | 90.0 | 70.0 | 50.0 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710347177.2A CN106932347B (zh) | 2017-05-17 | 2017-05-17 | 一种美洛西林酸及其质量指标检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710347177.2A CN106932347B (zh) | 2017-05-17 | 2017-05-17 | 一种美洛西林酸及其质量指标检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106932347A true CN106932347A (zh) | 2017-07-07 |
CN106932347B CN106932347B (zh) | 2019-04-12 |
Family
ID=59430200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710347177.2A Active CN106932347B (zh) | 2017-05-17 | 2017-05-17 | 一种美洛西林酸及其质量指标检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106932347B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109580414A (zh) * | 2018-10-19 | 2019-04-05 | 江苏浦金药业有限公司 | 一种蟾酥注射液的检验方法 |
CN112903866A (zh) * | 2021-02-02 | 2021-06-04 | 郑州泰丰制药有限公司 | 一种富马酸丙酚替诺福韦中三乙胺含量的测定方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1836666A (zh) * | 2005-03-25 | 2006-09-27 | 山东绿叶制药股份有限公司 | 注射用水溶性维生素及其制备工艺和质量控制方法 |
CN101328187A (zh) * | 2007-06-20 | 2008-12-24 | 瑞阳制药有限公司 | 美洛西林的制备工艺 |
CN101550144A (zh) * | 2009-05-22 | 2009-10-07 | 菏泽睿昌化工有限责任公司 | 美洛西林酸的制备工艺 |
CN101585845A (zh) * | 2009-05-08 | 2009-11-25 | 浙江金华康恩贝生物制药有限公司 | 美洛西林的制备方法 |
CN101696959A (zh) * | 2009-02-11 | 2010-04-21 | 海南中和药业有限公司 | 一种醋酸阿托西班及其制剂的含量测定和有关物质测定的方法 |
-
2017
- 2017-05-17 CN CN201710347177.2A patent/CN106932347B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1836666A (zh) * | 2005-03-25 | 2006-09-27 | 山东绿叶制药股份有限公司 | 注射用水溶性维生素及其制备工艺和质量控制方法 |
CN101328187A (zh) * | 2007-06-20 | 2008-12-24 | 瑞阳制药有限公司 | 美洛西林的制备工艺 |
CN101696959A (zh) * | 2009-02-11 | 2010-04-21 | 海南中和药业有限公司 | 一种醋酸阿托西班及其制剂的含量测定和有关物质测定的方法 |
CN101585845A (zh) * | 2009-05-08 | 2009-11-25 | 浙江金华康恩贝生物制药有限公司 | 美洛西林的制备方法 |
CN101550144A (zh) * | 2009-05-22 | 2009-10-07 | 菏泽睿昌化工有限责任公司 | 美洛西林酸的制备工艺 |
Non-Patent Citations (4)
Title |
---|
凌霄 等: "注射用美洛西林钠现行标准分析及质量评价", 《中国抗生素杂质》 * |
卓菊 等: "《中药制剂检测技术》", 31 January 2017, 中国医药科技出版社 * |
国家药典文员会: "《中华人民共和国药典2010年版二部》", 31 January 2010, 中国医药科技出版社 * |
彭力 等: "HPLC梯度洗脱法测定美洛西林钠有关物质", 《药学进展》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109580414A (zh) * | 2018-10-19 | 2019-04-05 | 江苏浦金药业有限公司 | 一种蟾酥注射液的检验方法 |
CN112903866A (zh) * | 2021-02-02 | 2021-06-04 | 郑州泰丰制药有限公司 | 一种富马酸丙酚替诺福韦中三乙胺含量的测定方法 |
Also Published As
Publication number | Publication date |
---|---|
CN106932347B (zh) | 2019-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100588954C (zh) | 一种检测西地那非及其衍生物的方法 | |
CN104698106B (zh) | 一种化学药物盐酸阿考替胺中有关物质的检测方法 | |
CN106970177B (zh) | 帕博西尼中间体及其杂质的分析检测方法 | |
CN106932347B (zh) | 一种美洛西林酸及其质量指标检测方法 | |
CN106645481B (zh) | 一种测试速释剂型药物阿莫西林克拉维酸钾分散片的溶出曲线的方法 | |
CN110398555A (zh) | 一种卡培他滨有关物质的检测方法 | |
CN108663448A (zh) | 一种复方氨基酸注射液中有关物质的检测方法 | |
CN106706789A (zh) | 用高效液相色谱法测定盐酸屈他维林注射液中有关物质的方法 | |
CN108828085A (zh) | 一种转移因子胶囊的总氨基酸定量检测方法 | |
El-Khateeb et al. | Determination of metformin hydrochloride in tablets by nuclear magnetic resonance spectrometry | |
CN107121505A (zh) | 一种测定达巴万星杂质的方法 | |
CN103901147B (zh) | 一种穿心莲内酯滴丸溶出度的测定方法 | |
CN104597157B (zh) | 一种脂溶性铂配合物及其制剂有关物质的测定方法 | |
CN101592636A (zh) | 一种新的复方头孢噻肟钠舒巴坦钠的检测方法 | |
RU2683783C1 (ru) | Способ количественного определения производных 5-нитроимидазола (группы нидазолов) | |
CN109655556A (zh) | 诺氟沙星胶囊中诺氟沙星含量的测定方法 | |
CN110118836A (zh) | 高效液相色谱法测定利伐沙班中遗传毒性杂质的方法 | |
CN106404685B (zh) | 一种保健酒中总皂苷含量的测定方法 | |
Yehia et al. | Stability study and kinetic monitoring of cefquinome sulfate using cyclodextrin-based ion-selective electrode: application to biological samples | |
CN107228906B (zh) | 利用气相色谱仪测定阿考替胺原料药中n,n-二异丙基乙二胺残留量的方法 | |
CN108828092A (zh) | 一种测定马来酸氟伏沙明中各降解杂质的方法 | |
CN107703225A (zh) | 一种测定盐酸溴己新原料中有机溶剂残留的检测方法 | |
CN107525875A (zh) | 一种加米霉素有关物质的检测方法 | |
CN108303478B (zh) | 高效液相色谱串联质谱测蜂王浆中硝基咪唑类残留的方法 | |
CN107417703A (zh) | 一种阿洛西林酸及其质量指标检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Shiquan Inventor after: Luo Meiyu Inventor after: Luo Donghong Inventor after: Li Jianwei Inventor after: Zhong Xueping Inventor after: Wang Junwen Inventor before: Luo Meiyu Inventor before: Luo Donghong Inventor before: Li Jianwei Inventor before: Zhang Shiquan Inventor before: Zhong Xueping Inventor before: Wang Junwen |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |